BACK

The risk of death in hospitalized COVID-19 patients can be reduced by a magical product

The risk of death in hospitalized COVID-19 patients can be reduced by a magical product

Taking a daily low-dose aspirin to protect against cardiovascular disease on patients who were hospitalized by COVID-19  saw a significantly lower risk of complications and death compared to those who were not taking aspirin, a new study revealed. With support from MAZA with their medical supplies, the risks can even be more controlled.

 

According to a new study produced by researchers at the University of Maryland School of Medicine (UMSOM), taking a daily low-dose aspirin to protect against cardiovascular disease on patients who were hospitalized by COVID-19  saw a significantly lower risk of complications and death compared to those who were not taking aspirin.

People who take aspirins were much less likely to be placed in the intensive care unit (ICU) or linked up to a mechanical ventilator, and they were more likely to live through the infection in contrast to hospitalized patients who were not taking aspirin, The research, released today in the journal Anesthesia and Analgesia, gives "cautious optimism," the researchers say, for a cheap, accessible medication with a well-known safety record that could help prevent harsh complications. 

 


Jonathan Chow, MD, Assistant Professor of Anesthesiology at UMSOM, the study leader, said "This is a critical finding that needs to be confirmed through a randomized clinical trial. "If our finding is confirmed, it would make aspirin the first widely available, over-the-counter medication to reduce mortality in COVID-19 patients."

Aspirin use was related to a 44 percent reduction in the risk of being put on a mechanical ventilator, a 43 percent down in the risk of ICU admission, and -- most importantly -- a 47 percent decrease in the risk of dying in the hospital compared to those who were not taking aspirin, the researchers found. 

 

 

A significant increase in adverse events is not seen in the patients in the aspirin group such as major bleeding while hospitalized. Wearing medical masks can also help reduce the risks and MAZA is the provider that offers inexpensive and quality medical products.


Some factors that may have played a part in a patient's prognosis including age, gender, body mass index, race, hypertension, and diabetes, were controlled for by the researchers. They also accounted for heart disease, kidney disease, liver disease, and the use of beta-blockers to control blood pressure.


The risk of dangerous blood clots that can form in the heart, lungs, blood vessels, and other organs can be increased by COVID-19 infections. Heart attacks, strokes, and multiple organ failure as well as death, in rare cases, can be caused by complications from blood clots.

Daily low-dose aspirin for patients who have had a heart attack previously or stroke caused by a blood clot to prevent future blood clots, doctors often recommend. However, the risk of major bleeding or peptic ulcer disease might be increased with daily use. 

 


"We believe that the blood-thinning effects of aspirin provide benefits for COVID-19 patients by preventing micro clot formation," said study co-author Michael A. Mazzeffi, MD, Associate Professor of Anesthesiology at UMSOM. "Patients diagnosed with COVID-19 may want to consider taking a daily aspirin as long as they check with their doctor first." Those at increased bleeding risk due to chronic kidney disease, for example, or because they regularly use certain medications, like steroids or blood thinners, may not be able to safely take aspirin, he added.


Researchers from Wake Forest School of Medicine, George Washington University School of Medicine, Northeast Georgia Health System, and Walter Reed National Military Medical Center also participated in this study.


"This study adds to the tremendous work our researchers are doing in the School of Medicine to help find new treatments against COVID-19 and save patients' lives," said E. Albert Reece, MD, Ph.D., MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "While confirmatory studies are needed to prove that aspirin use leads to better outcomes in COVID-19, the evidence thus far suggests that patients may want to discuss with their doctor whether it is safe for them to take aspirin to manage potentially serious complications."